Delcath Systems Value Stock - Dividend - Research Selection
Market price: 0,00 USD
Delcath Systems Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||-23.690.000|
|Free cash flow||-23.714.000|
|Liabilities & Shareholders equity||14.212.000|
|Diluted shares outstanding||25.900|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||67.849,00 USD|
|Raw Data Source|
Description of the company
Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs. On April 13, 2011, it received Conformite Europeenne (CE) mark approval for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT System).